Information Provided By: 
Fly News Breaks for November 2, 2018
EGRX
Nov 2, 2018 | 09:19 EDT
RBC Capital analyst Randall Stanicky lowered his price target on Eagle Pharmaceuticals to $64, saying that the Q3 results came in line with the negative pre-announcement but also highlighted the company's "recent pipeline setbacks and outlook". The analyst keeps his Outperform rating on the shares based on Eagle Pharma's position "to drive value from the development of improved formulations of existing on-market products", but contends that "strategic M&A" needs to play a role to bolster its internal pipeline following its recent setbacks.
News For EGRX From the Last 2 Days
There are no results for your query EGRX
